Method for inactivating virus or bacterium

Through the combination of low-concentration quaternary ammonium salt surfactant and aliphatic alcohol, a sprayer forms bubbles and adheres to the target surface, solving the problems of high toxicity, high cost and easy dripping of spray liquid in the prior art, realizing the Effective viral or bacterial inactivation effects.

CN118890962APending Publication Date: 2024-11-01KAO CORP
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202380019487.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-09-07
Filing Date
2023-01-18
Publication Date
2024-11-01

AI Technical Summary

Technical Problem

Due to its high toxicity and high cost, existing quaternary ammonium surfactants are difficult to achieve high-efficiency inactivation of viruses or bacteria at low concentrations, and the spray-type bactericidal liquid is prone to dripping, resulting in a reduced inactivation performance.

Method used

A combination of a low-concentration quaternary ammonium salt-type surfactant and aliphatic alcohol is used to form a bubble-like adhesion to the object surface through a sprayer, which improves contact time and adhesion persistence, thereby improving the inactivation effect of viruses or bacteria.

Benefits of technology

Even under low concentration conditions, envelope viruses, Moracia and micrococci can be effectively inactivated, and the bubble-like adhesion avoids dripping, significantly improving the bactericidal performance.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004969990340000031
    Figure BDA0004969990340000031
  • Figure BDA0004969990340000032
    Figure BDA0004969990340000032
  • Figure BDA0004969990340000081
    Figure BDA0004969990340000081
Patent Text Reader

Abstract

The present invention provides a method for inactivating a virus or a bacterium, which has a high inactivation effect on an enveloped virus, a bacterium belonging to the genus Moraxella, and a bacterium belonging to the genus Micrococcus, even under use conditions in which a quaternary ammonium salt-type surfactant is at a low concentration. In this method for inactivating a virus or a bacterium, a treatment liquid containing (A) a quaternary ammonium salt-type surfactant, (B) an aliphatic alcohol, and water is brought into contact with the surface of a subject, and one or more viruses or bacteria selected from the group consisting of enveloped viruses, Moraxella bacteria, and Micrococcus bacteria present on the surface of the subject are inactivated.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a method for inactivating one or more viruses or bacteria selected from the group consisting of enveloped viruses, bacteria of the genus Moraxella and bacteria of the genus Micrococcus. Background Art

[0002] Quaternary ammonium surfactants are widely used as substrates for inactivating viruses or bacteria. On the other hand, since quaternary ammonium surfactants are highly toxic to aquatic organisms, their large-scale use and disposal are considered as major issues. In addition, in order to suppress the cost of the base agent, a technology that exhibits high performance at low concentrations is also required. In addition, if the concentration of the quaternary ammonium surfactant in the treatment solution can be reduced, a simple and safe treatment solution formulation proposal that does not require washing can be realized, which also has great advantages from the perspective of product development.

[0003] In the specification of U.S. Patent No. 6143703, an aqueous concentrated liquid disinfectant composition is disclosed, which contains a vegetable oil component, a bactericidal cationic surfactant with bactericidal properties, an organic solvent component, a vegetable oil-soluble surfactant, an alkyl polyoxycarboxylate and an alkyl aryl polyoxycarboxylate, and a biphenyl solvent component.

[0004] Japanese Patent Application Publication No. 2020-524201 discloses an improved chemical formulation comprising a quaternary ammonium salt surfactant and lauryl alcohol.

[0005] In the Chinese Patent Publication No. 105767049, an animal disinfectant containing benzalkonium bromide and lauryl alcohol is disclosed.

[0006] In the Chinese Patent Publication No. 112335655, an environmentally friendly composite fungicide containing alkyl dimethyl benzyl ammonium chloride and a long-chain fatty alcohol is disclosed.

[0007] European Patent No. 2542211 discloses an antimicrobial oil-in-water emulsion containing didecyldimethylammonium chloride and an aliphatic alcohol having 12 to 22 carbon atoms. Summary of the invention

[0008] The present invention provides a method for inactivating viruses or bacteria, which has a high inactivation effect on enveloped viruses, Moraxella bacteria and Micrococcus bacteria even when a quaternary ammonium salt type surfactant is used at a low concentration.

[0009] Here, the inactivation effect of viruses or bacteria refers to killing part or all of the viruses or bacteria and losing the activity such as the infectivity and toxicity of the viruses or bacteria.

[0010] The present invention relates to a method for inactivating viruses or bacteria, wherein a treatment liquid (hereinafter referred to as the treatment liquid of the present invention) containing (A) a quaternary ammonium salt surfactant (hereinafter referred to as the (A) component), (B) an aliphatic alcohol (hereinafter referred to as the (B) component) and water is brought into contact with a surface of an object, thereby inactivating one or more viruses or bacteria selected from enveloped viruses, bacteria of the genus Moraxella and bacteria of the genus Micrococcus present on the surface of the object.

[0011] According to the present invention, there can be provided a method for inactivating viruses or bacteria, which has a high inactivation effect on enveloped viruses, Moraxella bacteria, and Micrococcus bacteria even when a quaternary ammonium salt-type surfactant is used at a low concentration.

[0012] In addition, under the condition of using the sterilizing liquid at a low concentration, the sterilizing liquid may drip from the surface of the object, and the inactivation performance of viruses or bacteria may be reduced. Therefore, by spraying the sterilizing liquid onto the object using a sprayer and continuously adhering to the surface of the object in the form of bubbles, dripping is suppressed and the contact time is prolonged, thereby improving the performance of inactivating viruses or bacteria. However, even if the conventional sterilizing liquid is sprayed onto the object using a sprayer and adhering to the surface of the object in the form of bubbles, the bubbles will burst, and the liquid will not remain on the surface of the object due to dripping, and the inactivation performance of viruses or bacteria will be reduced.

[0013] In the virus or bacteria inactivation method of the present invention, when the treatment liquid of the present invention is made into a bubble and contacts the surface of an object, the durability of the bubbles is greatly improved. Therefore, even if the liquid volume is the same, the treatment liquid of the present invention will adhere to a large area and will not drip. Therefore, it can adhere to the surface of the object for a long time, thereby further improving the bactericidal performance. DETAILED DESCRIPTION

[0014] [Methods for inactivating viruses or bacteria]

[0015] The method for inactivating viruses or bacteria of the present invention has a high inactivation effect on enveloped viruses, Moraxella bacteria, and Micrococcus bacteria even when the quaternary ammonium salt-type surfactant as the component (A) of the present invention is used at a low concentration. Although the reason for this is not necessarily certain, it can be inferred as follows.

[0016] When the treatment liquid of the present invention is brought into contact with the surface of an object where the above-mentioned virus or bacteria exists, the aliphatic alcohol as the component (B) of the present invention is adsorbed to the virus or bacteria before the quaternary ammonium salt type surfactant as the component (A), and the virus or bacteria is hydrophobized. It is believed that the amount of adsorption of the quaternary ammonium salt type surfactant increases due to the hydrophobization of the virus or bacteria, and the inactivation effect is improved.

[0017] <(A)Component>

[0018] The treatment liquid of the present invention contains a quaternary ammonium salt-type surfactant as the component (A).

[0019] The component (A) is preferably one or more selected from (a1) a compound represented by the following general formula (a1) (hereinafter referred to as the component (a1)) and (a2) a compound represented by the following general formula (a2) (hereinafter referred to as the component (a2)).

[0020] [Chemistry 1]

[0021]

[0022] 〔In the formula, R 1a is an aliphatic hydrocarbon group having 8 or more and 18 or less carbon atoms, R 2a is a group selected from an aliphatic hydrocarbon group having 8 to 18 carbon atoms, an alkyl group having 1 to 3 carbon atoms, and a hydroxyalkyl group having 1 to 3 carbon atoms, and R 3a and R 4a Each is independently a group selected from an alkyl group having 1 to 3 carbon atoms and a hydroxyalkyl group having 1 to 3 carbon atoms, and X- is an anion.]

[0023] [Chemistry 2]

[0024]

[0025] 〔In the formula, R 5a is an aliphatic hydrocarbon group having 8 or more and 18 or less carbon atoms, R 6a and R 7a Each is independently a group selected from an alkyl group having 1 to 3 carbon atoms and a hydroxyalkyl group having 1 to 3 carbon atoms, and X- is an anion.]

[0026] In the general formula (a1), R 1a The carbon number of R is 8 or more from the viewpoint of virus or bacteria inactivation performance, and is preferably 18 or less, more preferably 14 or less, and further preferably 10 or less from the viewpoint of water solubility. 1a It is preferably an alkyl group or an alkenyl group, and more preferably an alkyl group.

[0027] In the general formula (a1), R 2a It is a group selected from an aliphatic hydrocarbon group having 8 to 18 carbon atoms, an alkyl group having 1 to 3 carbon atoms, and a hydroxyalkyl group having 1 to 3 carbon atoms.

[0028] In R 2a In the case of an aliphatic hydrocarbon group having 8 or more and 18 or less carbon atoms, R 2aFrom the viewpoint of virus or bacteria inactivation performance, it is an alkyl or alkenyl group with 8 or more, and from the viewpoint of water solubility, it is preferably an alkyl or alkenyl group with 18 or less, more preferably 14 or less, and further preferably 10 or less, and is more preferably an alkyl group.

[0029] In the general formula (a1), R 3a and R 4a Each is independently a group selected from an alkyl group having 1 to 3 carbon atoms and a hydroxyalkyl group having 1 to 3 carbon atoms. 3a and R 4a Each independently is preferably an alkyl group having 1 to 3 carbon atoms. Examples of the alkyl group having 1 to 3 carbon atoms include methyl, ethyl, and propyl. Examples of the hydroxyalkyl group having 1 to 3 carbon atoms include hydroxymethyl, hydroxyethyl, and hydroxypropyl.

[0030] In the general formula (a1), X - As anions, halogen ions such as chloride ions, bromide ions and iodide ions can be cited. In addition, alkyl sulfate ions having a carbon number of 1 or more and 3 or less can be cited, such as methyl sulfate ions, ethyl sulfate ions and propyl sulfate ions.

[0031] Preferred compounds of the compound of general formula (a1) include one or more selected from N-alkyl-N,N,N-trimethylammonium salts in which the number of carbon atoms in the alkyl group is from 12 to 18, N,N-dialkyl-N,N-dimethyl-ammonium salts in which the number of carbon atoms in the alkyl group is from 8 to 16, and N-alkyl-N,N-dimethyl-N-ethylammonium salts in which the number of carbon atoms in the alkyl group is from 12 to 16.

[0032] In the general formula (a2), R 5a It is an aliphatic hydrocarbon group having 8 or more and 18 or less carbon atoms. 5a The carbon number of R is preferably 8 or more, more preferably 10 or more, and further preferably 12 or more, and is preferably 18 or less, more preferably 16 or less, and further preferably 14 or less, from the viewpoint of virus or bacteria inactivation performance. 5a It is preferably an alkyl group or an alkenyl group, and more preferably an alkyl group.

[0033] In the general formula (a2), R 6a and R 7a Each is independently a group selected from an alkyl group having 1 to 3 carbon atoms and a hydroxyalkyl group having 1 to 3 carbon atoms. 6a and R 7aEach independently is preferably an alkyl group having 1 to 3 carbon atoms. Examples of the alkyl group having 1 to 3 carbon atoms include methyl, ethyl, and propyl. Examples of the hydroxyalkyl group having 1 to 3 carbon atoms include hydroxymethyl, hydroxyethyl, and hydroxypropyl.

[0034] In the general formula (a2), X- is an anion. Examples of the anion include halogen ions such as chloride ions, bromide ions, and iodide ions. In addition, examples include alkyl sulfate ions having a carbon number of 1 or more and 3 or less, such as methyl sulfate ions, ethyl sulfate ions, and propyl sulfate ions.

[0035] Specific examples of the compound of the general formula (a2) include N-octyl-N,N-dimethyl-N-benzyl ammonium salt, N-decyl-N,N-dimethyl-N-benzyl ammonium salt, N-dodecyl-N,N-dimethyl-N-benzyl ammonium salt, N-tridecyl-N,N-dimethyl-N-benzyl ammonium salt, N-tetradecyl-N,N-dimethyl-N-benzyl ammonium salt, N-pentadecyl-N,N-dimethyl-N-benzyl ammonium salt, N-hexadecyl-N,N-dimethyl-N-benzyl ammonium salt, N-dodecyl-N,N-diethyl-N-benzyl ammonium salt, N-tridecyl-N,N-dimethyl-N-benzyl ammonium salt, N-tetradecyl-N,N-dimethyl-N-benzyl ammonium salt, N-pentadecyl-N,N-dimethyl-N-benzyl ammonium salt, N-hexadecyl-N,N-dimethyl-N-benzyl ammonium salt, N-dodecyl-N,N-diethyl-N-benzyl ammonium salt, N-tridecyl-N,N- One or more compounds selected from diethyl-N-benzylammonium salt, N-tetradecyl-N,N-diethyl-N-benzylammonium salt, N-pentadecyl-N,N-diethyl-N-benzylammonium salt, N-hexadecyl-N,N-diethyl-N-benzylammonium salt, N-dodecyl-N-methyl-N-ethyl-N-benzylammonium salt, N-tridecyl-N-methyl-N-ethyl-N-benzylammonium salt, N-tetradecyl-N-methyl-N-ethyl-N-benzylammonium salt, N-pentadecyl-N-methyl-N-ethyl-N-benzylammonium salt and N-hexadecyl-N-methyl-N-ethyl-N-benzylammonium salt.

[0036] In the treatment liquid of the present invention, as component (A), from the viewpoint of virus or bacteria inactivation performance, it is preferred to contain component (a1), more preferably an N,N-dialkyl-N,N-dimethyl-ammonium salt having an alkyl group with 8 to 16 carbon atoms, and further preferably a didecyldimethylammonium salt.

[0037] <(B) Ingredient>

[0038] The treatment liquid of the present invention contains an aliphatic alcohol as the component (B).

[0039] The carbon number of the aliphatic alcohol is preferably 8 or more, more preferably 10 or more, further preferably 12 or more, from the viewpoint of virus or bacteria inactivation performance and from the viewpoint of foaming property and sustainability of the foams since the aliphatic alcohol adheres to the surface of the object in the form of bubbles. Furthermore, it is preferably 16 or less, more preferably 14 or less, further preferably 12 or less, and further preferably 12.

[0040] The component (B) is preferably an aliphatic alcohol having an aliphatic hydrocarbon group, preferably a linear or branched alkyl group, or a linear or branched alkenyl group, more preferably a linear or branched alkyl group, and further preferably a linear alkyl group. The component (B) is preferably an aliphatic primary alcohol, further preferably a linear alkyl group.

[0041] Component (B) may specifically include at least one selected from octanol, decanol, dodecyl alcohol, tetradecyl alcohol and hexadecyl alcohol. From the viewpoint of virus or bacteria inactivation performance, at least one selected from decanol, dodecyl alcohol and tetradecyl alcohol is preferred, at least one selected from dodecyl alcohol and tetradecyl alcohol is more preferred, and dodecyl alcohol is further preferred.

[0042] In the treatment liquid of the present invention, the content of component (A) is preferably 0.1 ppm or more, more preferably 1 ppm or more, further preferably 5 ppm or more, further preferably 20 ppm or more, further preferably 50 ppm or more, from the viewpoint of virus or bacteria inactivation performance, and is preferably 4000 ppm or less, more preferably 3000 ppm or less, further preferably 1000 ppm or less, further preferably 500 ppm or less, further preferably 300 ppm or less, further preferably 200 ppm or less, further preferably 150 ppm or less, further preferably 100 ppm or less, from the viewpoint of cost.

[0043] In addition, in this invention, the value converted into chloride salt is used for stipulating the mass of (A) component.

[0044] In the treatment liquid of the present invention, it is preferred to contain components (a1) and (a2) as component (A) from the viewpoint of virus or bacteria inactivation performance and cost. Component (a1) is preferably an N,N-dialkyl-N,N-dimethyl-ammonium salt having an alkyl group with 8 to 16 carbon atoms, and more preferably a didecyldimethylammonium salt.

[0045] In the treatment liquid of the present invention, when containing component (a1) and component (a2), the mass ratio (a2) / (a1) of the content of component (a1) to the content of component (a2) is preferably 0 / 10 or more, more preferably 1.5 / 8.5 or more, and further preferably 2 / 8 or more from the viewpoint of cost, and is preferably 8 / 2 or less, more preferably 7 / 3 or less, further preferably 6 / 4 or less, and further preferably 4 / 6 or less from the viewpoint of virus or bacteria inactivation performance.

[0046] In the treatment liquid of the present invention, when containing components (a1) and (a2), the content of components (a1) and (a2) in component (A) is preferably 50% by mass or more, more preferably 80% by mass or more, and is preferably 100% by mass or less, more preferably substantially 100% by mass, from the viewpoint of virus or bacteria inactivation performance.

[0047] In the treatment liquid of the present invention, the content of component (B) is preferably 0.1 ppm or more, more preferably 1 ppm or more, further preferably 10 ppm or more, further preferably 20 ppm or more, further preferably 50 ppm or more, from the viewpoint of virus or bacteria inactivation performance and from the viewpoint of foaming property and persistence of the bubbles because the component (B) adheres to the surface of the object in the form of bubbles. Furthermore, from the viewpoint of cost, it is preferably 1500 ppm or less, more preferably 1000 ppm or less, further preferably 500 ppm or less, further preferably 250 ppm or less, further preferably 150 ppm or less, further preferably 100 ppm or less, further preferably 50 ppm or less.

[0048] In the treatment liquid of the present invention, the mass ratio (B) / (A) of the content of component (A) to the content of component (B) is preferably 1 / 4 or more, more preferably 1 / 3 or more, and further preferably 1 / 2 or more, from the viewpoint of virus or bacteria inactivation performance and from the viewpoint of foaming property and sustainability of the bubbles because the components adhere to the surface of the object in the form of bubbles. Furthermore, from the viewpoint of virus or bacteria inactivation performance and liquid phase stability of the treatment liquid and from the viewpoint of foaming property and sustainability because the components adhere to the surface of the object in the form of bubbles, it is preferably 10 / 1 or less, more preferably 7 / 1 or less, further preferably 5 / 1 or less, further preferably 3 / 1 or less, and further preferably 2 / 1 or less.

[0049] The treatment liquid of the present invention contains water. In the treatment liquid of the present invention, the water content is preferably 90% by mass or more, more preferably 99% by mass or more, further preferably 99.9% by mass or more, and preferably 99.999% by mass or less, more preferably 99.99% by mass or less, further preferably 99.95% by mass or less.

[0050] The treatment liquid of the present invention may contain (C) a surfactant [excluding component (A)] [hereinafter referred to as component (C)] from the viewpoint of cleaning performance on the surface of the object and foaming performance when the treatment liquid is sprayed. From the viewpoint of adhesion to the surface of the object, foaming performance when the treatment liquid is sprayed is important.

[0051] Examples of the component (C) include at least one selected from the group consisting of (C1) anionic surfactants [hereinafter referred to as component (C1)], (C2) nonionic surfactants [hereinafter referred to as component (C2)], (C3) semipolar surfactants [hereinafter referred to as component (C3)], and (C4) amphoteric surfactants [hereinafter referred to as component (C4)].

[0052] The component (C1) may be an alkyl sulfate having an alkyl group of 8 to 22 carbon atoms, an alkylbenzenesulfonic acid having an alkyl group of 8 to 22 carbon atoms, a polyoxyalkylene alkyl ether sulfate having an alkyl group of 8 to 22 carbon atoms (the oxyalkylene group is an oxyalkylene group having 2 or 3 carbon atoms, preferably an oxyethylene group, and the average number of added moles of the oxyalkylene group is 0.5 to 5, preferably 0.5 to 3), a fatty acid having 8 to 22 carbon atoms, and salts thereof.

[0053] The component (C2) may be a polyoxyalkylene alkyl ether having an alkyl group with 8 to 22 carbon atoms (the oxyalkylene group is an oxyalkylene group having 2 or 3 carbon atoms, preferably an oxyethylene group, and the average number of moles of the oxyalkylene group added is 3 to 50, preferably 3 to 20), an alkyl glucoside having an alkyl group with 8 to 14 carbon atoms (the average degree of condensation of a sugar skeleton such as glucose is 1 to 5, preferably 1 to 2), and a polyoxyalkylene adduct of pentaerythritol (the oxyalkylene group is an oxyalkylene group having 2 or 3 carbon atoms, preferably an oxypropylene group, and the average number of moles of the oxyalkylene group added is 3 to 15, preferably 5 to 8).

[0054] Examples of the component (C3) include amine oxide-type surfactants having one or more, preferably one, alkyl or alkenyl group having 7 to 22 carbon atoms.

[0055] As the amine oxide type surfactant, a compound represented by the following general formula (c3) is suitable.

[0056] [Chemistry 3]

[0057]

[0058] 〔In the formula, R 1c represents an alkyl group or an alkenyl group having 7 to 22 carbon atoms, more preferably an alkyl group, R 2c and R 3c are the same or different and represent an alkyl group having 1 to 3 carbon atoms. D represents a -NHC(=O)- group or a -C(=O)NH- group, and E represents an alkylene group having 1 to 5 carbon atoms. q and p represent q=0 and p=0 or q=1 and p=1.

[0059] In the above general formula (c3), when q=1 and p=1, R 1c From the viewpoint of foaming properties, it is a hydrocarbon group having 9 or more, preferably 11 or more, and 18 or less, preferably 16 or less, and more preferably 14 or less carbon atoms, and is preferably an alkyl group.

[0060] In addition, when q = 0 and p = 0, about R 1c , from the viewpoint of foaming properties, is a hydrocarbon group having 10 or more, preferably 12 or more, and 18 or less, preferably 16 or less, and more preferably 14 or less carbon atoms, and is preferably an alkyl group. In the present invention, q=0 and p=0 are preferred. R 2c , R 3c A methyl group having 1 carbon number is preferred.

[0061] Examples of the component (C4) include betaine-type surfactants having one or more, preferably one, alkyl or alkenyl group having 7 to 22 carbon atoms, and preferably sulfobetaine-type surfactants or carboxybetaine-type surfactants.

[0062] As the betaine-type surfactant, a compound represented by the following general formula (c4) is suitable.

[0063] [Chemistry 4]

[0064]

[0065] 〔In the formula, R 4c is an alkyl or alkenyl group having 7 to 18 carbon atoms, R 5c is an alkylene group having 1 to 6 carbon atoms. A is a group selected from -COO-, -CONH-, -OCO-, -NHCO-, and -O-, and r is a number of 0 or 1. 6c , R 7c is an alkyl group or a hydroxyalkyl group having 1 to 3 carbon atoms, R 8c is an alkylene group having 1 to 5 carbon atoms which may be substituted by a hydroxyl group.3 - 、-OSO 3 - 、-COO - . 〕

[0066] In the general formula (c4), regarding R 4c , from the viewpoint of foaming properties, it is an alkyl or alkenyl group having 7 or more, preferably 10 or more, and 18 or less, preferably 14 or less, and more preferably 12 or less carbon atoms, and is preferably an alkyl group.

[0067] A is preferably -COO- or -CONH-, more preferably -CONH-.

[0068] R 1c The carbon number of is preferably 2 or 3.

[0069] r is preferably 0.

[0070] R 6c , R 7c Preferred is methyl.

[0071] R 8c The carbon number of is preferably 1.

[0072] B is preferably -COO-.

[0073] Specifically, the betaine-type surfactant includes at least one selected from alkylcarboxybetaines, alkylamidecarboxybetaines, alkylsulfobetaines, alkylhydroxysulfobetaines, alkylamidehydroxysulfobetaines, and alkylamino fatty acid salts. From the viewpoint of foaming properties, at least one selected from alkylamidepropyl-N,N-dimethylcarboxybetaines and alkyl-N,N-dimethylacetic acid betaines is preferred. The carbon number of these alkyl groups is 7 or more, preferably 10 or more, and 18 or less, preferably 14 or less, and more preferably 12 or less.

[0074] In the case where the treatment liquid of the present invention contains component (C), the content of component (C) in the treatment liquid of the present invention is preferably 0.5 ppm or more, more preferably 1 ppm or more, further preferably 10 ppm or more, further preferably 100 ppm or more, further preferably 500 ppm or more, and is preferably 30,000 ppm or less, more preferably 10,000 ppm or less, further preferably 5,000 ppm or less, further preferably 2,500 ppm or less, further preferably 1,000 ppm or less.

[0075] In addition, in this invention, when using (C1) component as (C) component, the value converted into sodium salt is used for the regulation of the mass of (C1) component.

[0076] In the case where the treatment liquid of the present invention contains component (C1), the content of component (C1) in the treatment liquid of the present invention is, from the viewpoint of foaming property, preferably 5 ppm or more, more preferably 10 ppm or more, further preferably 20 ppm or more, further preferably 100 ppm or more, further preferably 500 ppm or more, further preferably 800 ppm or more, and, from the viewpoint of bactericidal property, preferably 10000 ppm or less, more preferably 8000 ppm or less, further preferably 6000 ppm or less, further preferably 4000 ppm or less, further preferably 3000 ppm or less.

[0077] In the case where the treatment liquid of the present invention contains component (C2), the content of component (C2) in the treatment liquid of the present invention is, from the viewpoint of foaming property, preferably 5 ppm or more, more preferably 10 ppm or more, further preferably 50 ppm or more, further preferably 200 ppm or more, further preferably 500 ppm or more, further preferably 1000 ppm or more, and preferably 30000 ppm or less, more preferably 10000 ppm or less, further preferably 8000 ppm or less, further preferably 5000 ppm or less, further preferably 4000 ppm or less.

[0078] In the case where the treatment liquid of the present invention contains component (C3), the content of component (C3) in the treatment liquid of the present invention is, from the viewpoint of foaming property, preferably 5 ppm or more, more preferably 10 ppm or more, further preferably 20 ppm or more, further preferably 100 ppm or more, further preferably 200 ppm or more, further preferably 500 ppm or more, and is preferably 10,000 ppm or less, more preferably 5,000 ppm or less, further preferably 2,000 ppm or less, further preferably 1,500 ppm or less, further preferably 1,000 ppm or less.

[0079] In the case where the treatment liquid of the present invention contains component (C4), the content of component (C4) in the treatment liquid of the present invention is, from the viewpoint of foaming property, preferably 5 ppm or more, more preferably 20 ppm or more, further preferably 50 ppm or more, further preferably 300 ppm or more, more preferably 500 ppm or more, further preferably 700 ppm or more, and is preferably 30,000 ppm or less, more preferably 10,000 ppm or less, further preferably 8,000 ppm or less, further preferably 5,000 ppm or less, further preferably 3,000 ppm or less.

[0080] The treatment liquid of the present invention may contain (D) a water-soluble organic solvent [excluding the component (B)] (hereinafter referred to as the component (D)] from the viewpoint of solubility of the base.

[0081] The water-soluble organic solvent in the present invention refers to a solvent that dissolves 20 g or more in 100 g of deionized water at 20°C.

[0082] The base herein refers to the component (A) or the component (B).

[0083] Component (D) may be one or more selected from (D1) a polyol having 2 to 4 carbon atoms (hereinafter referred to as component (D1)), (D2) a di- or tri-alkylene glycol having 2 to 4 carbon atoms in an alkylene glycol unit (hereinafter referred to as component (D2)), (D3) a monoalkoxy (methoxy, ethoxy, propoxy, butoxy) ether, phenoxy or phenoxy ether of a di- or tetra-alkylene glycol having 2 to 4 carbon atoms in an alkylene glycol unit (hereinafter referred to as component (D3)), and (D4) a monohydric alcohol having 1 to 3 carbon atoms (hereinafter referred to as component (D4)).

[0084] From the viewpoint of mildness to the skin, the component (D) is preferably one or more selected from the group consisting of the component (D1), the component (D2) and the component (D3).

[0085] The component (D) is preferably a water-soluble organic solvent having 2 or more carbon atoms, preferably 3 or more carbon atoms, and 10 or less carbon atoms, preferably 8 or less carbon atoms.

[0086] Specifically, as the (D1) component, ethylene glycol, propylene glycol, glycerol, and isoprene glycol can be cited, as the (D2) component, diethylene glycol and dipropylene glycol can be cited, and as the (D3) component, propylene glycol monomethyl ether, propylene glycol monoethyl ether, diethylene glycol monobutyl ether (also referred to as butyl diethylene glycol, etc.), phenoxyethanol, phenoxy triethylene glycol, and phenoxy isopropanol can be cited, and these can be used alone or in combination. As the (D) component, preferably one or more water-soluble organic solvents selected from propylene glycol, dipropylene glycol, diethylene glycol monobutyl ether, phenoxyethanol, styrene glycol, and phenoxy isopropanol are preferred. The (D) component is preferably a water-soluble organic solvent having an alkoxy group, and more preferably diethylene glycol monobutyl ether.

[0087] It should be noted that component (D4) is an alcohol used as a bactericidal and disinfecting alcohol and obtains a bactericidal effect by containing it in high concentrations. However, when it frequently contacts the skin and other human bodies, it may cause skin problems such as rough hands, so it may be dangerous. Therefore, the treatment liquid of the present invention may not contain component (D4).

[0088] In the case where the treatment liquid of the present invention contains the component (D4), the content of the component (D4) in the treatment liquid of the present invention is preferably 100000 ppm or less, more preferably 30000 ppm or less, further preferably 10000 ppm or less, further preferably 5000 ppm or less, further preferably 2500 ppm or less, further preferably 1000 ppm or less, further preferably 500 ppm or less, further preferably 250 ppm or less, further preferably 100 ppm or less, further preferably 50 ppm or less, further preferably 10 ppm or less, further preferably 1 ppm or less, further preferably 1 ppm or less, from the viewpoint of irritation to the skin. In addition, the treatment liquid of the present invention may not contain an alcohol having 1 to 3 carbon atoms.

[0089] In the case where the treatment liquid of the present invention contains component (D) (excluding component (D4)), the content of component (D) (excluding component (D4)), especially components (D1) to (D3) in the treatment liquid of the present invention is preferably 0.5 ppm or more, more preferably 1 ppm or more, further preferably 10 ppm or more, further preferably 50 ppm or more, further preferably 100 ppm or more, and preferably 50,000 ppm or less, more preferably 10,000 ppm or less, further preferably 5,000 ppm or less.

[0090] The treatment liquid of the present invention may contain (E) an organic acid or a salt thereof (hereinafter referred to as component (E)) from the viewpoint of bactericidal properties in the presence of a hardness component.

[0091] From the viewpoint of bactericidal properties in the presence of hardness components, component (E) may include at least one selected from caprylic acid, sorbic acid, caproic acid, propionic acid, formic acid, acetic acid, benzoic acid, salicylic acid, lactic acid, tartaric acid, malic acid, glycolic acid, gluconic acid, citric acid, maleic acid, fumaric acid, oxalic acid, adipic acid, glutamic acid, succinic acid, sebacic acid, azelaic acid, and salts thereof.

[0092] Examples of the salt of the component (E) include one or more selected from the group consisting of sodium salts, potassium salts, magnesium salts, and calcium salts.

[0093] The component (E) is preferably one or more selected from the group consisting of gluconic acid, citric acid, and salts thereof, from the viewpoint of bactericidal properties in the presence of a hardness component.

[0094] In the case where the treatment liquid of the present invention contains component (E), the content of component (E) in the treatment liquid of the present invention is preferably 0.01 ppm or more, more preferably 0.1 ppm or more, further preferably 1 ppm or more, further preferably 5 ppm or more, further preferably 20 ppm or more, further preferably 40 ppm or more, further preferably 80 ppm or more, and is preferably 700 ppm or less, more preferably 500 ppm or less, further preferably 350 ppm or less, from the viewpoint of bactericidal properties in the presence of hardness components.

[0095] In addition, in this invention, the value converted into sodium salt is used for stipulating the mass of (E) component.

[0096] The treatment liquid of the present invention has a high inactivation effect on enveloped viruses, bacteria of the genus Moraxella and bacteria of the genus Micrococcus even if it does not contain a bactericidal agent other than the component (A).

[0097] When a bactericide is used in combination, specific examples of the bactericide include at least one selected from the group consisting of triclosan, isopropylmethylphenol, resorcinol, triclocarban, chlorhexidine chloride, chlorhexidine gluconate, hydrogen peroxide, povidone iodine, and iodine tincture.

[0098] In the case where the treatment liquid of the present invention contains a fungicide other than component (A), the content of the fungicide other than component (A) in the treatment liquid of the present invention is preferably 1000 ppm or less, more preferably 100 ppm or less, further preferably 50 ppm or less, further preferably 10 ppm or less, further preferably 1 ppm or less, further preferably 0.5 ppm or less from the viewpoint of cost. In addition, the treatment liquid of the present invention may not contain a fungicide other than component (A).

[0099] The treatment liquid of the present invention may contain ingredients such as inorganic salts, inorganic acids, fragrances (natural fragrances, synthetic fragrances), thickeners, gelling agents, polymer compounds (dispersants), hydrotropes, humectants, preservatives, antioxidants, light stabilizers, preservatives, buffers, etc. (excluding ingredients corresponding to components (A) to (E)) within a range that does not impair the effects of the present invention.

[0100] In the treatment liquid of the present invention, the total content of components (A) to (E) is preferably 0.001 mass % or more, more preferably 0.005 mass % or more, and is preferably 1.0 mass % or less, more preferably 0.1 mass % or less, and further preferably 0.01 mass % or less, from the viewpoint of cost.

[0101] In the treatment liquid of the present invention, the pH at 25°C measured by the glass electrode method is preferably 3 or more, more preferably 4 or more, further preferably 5 or more, and is preferably 10 or less, more preferably 9 or less, further preferably 8 or less from the viewpoint of skin irritation.

[0102] The treatment liquid of the present invention can be used in the form of liquid, gel or paste, for example. According to the form of use, the treatment liquid of the present invention can appropriately contain a soluble carrier such as water or a solvent, a gelling agent and the like.

[0103] The method for inactivating viruses or bacteria of the present invention targets at least one virus or bacteria selected from the group consisting of enveloped viruses, bacteria of the genus Moraxella and bacteria of the genus Micrococcus.

[0104] The enveloped virus refers to a single-stranded (+) RNA virus, a single-stranded (-) RNA virus, a double-stranded RNA virus, a single-stranded DNA virus, and a double-stranded DNA virus having a lipid layer or a lipid bilayer on the virus surface.

[0105] Examples of enveloped viruses include herpes virus, influenza virus, paramyxovirus, rabies virus, respiratory syncytial virus, coronavirus, HIV, natural poxvirus, hepatitis B virus, hepatitis C virus, hepatitis D virus, rubella virus, SARS coronavirus (SARS-CoV), SARS coronavirus 2 (SARS-CoV-2), MERS coronavirus (MERS-CoV), bacteriophage viruses, and the like.

[0106] Examples of the bacteria belonging to the genus Moraxella include Moraxella sp. and Moraxella osloensis.

[0107] Examples of the bacteria belonging to the genus Micrococcus include Micrococcus luteus, Micrococcus lylae, and Micrococcus aloeverae.

[0108] The method for inactivating viruses or bacteria of the present invention targets influenza virus, human coronavirus, Moraxella osloensis, or Micrococcus luteus, particularly influenza virus, Moraxella osloensis, or Micrococcus luteus, and has a high inactivation effect on these bacteria or viruses.

[0109] In the method for inactivating viruses or bacteria of the present invention, examples of the target surface to be contacted with the treatment solution of the present invention include (1) surfaces of hard articles and (2) surfaces of livestock or livestock-breeding equipment.

[0110] Examples of hard objects include bathrooms, toilets, kitchens, floors, doorknobs, tableware, food processing equipment, tables, chairs, walls, and other hard objects with hard surfaces. These hard objects may be used at home or in public facilities, factories, such as swimming pools, bathhouses, cafeterias, hospitals, and the like.

[0111] Examples of livestock include cattle, pigs, chickens, and the like.

[0112] Examples of livestock breeding equipment include floors, walls, entrances and exits of livestock sheds, pig pens, chicken coops, and the like, items installed and arranged in these facilities, and tools and equipment used for work performed in these facilities.

[0113] As a method for contacting the treatment liquid of the present invention with the surface of the object where the virus or bacteria as the target exists, there can be mentioned a method of spraying or applying the treatment liquid of the present invention on the surface of the object where the virus or bacteria as the target exists or is thought to exist; a method of immersing the surface of the object in the treatment liquid of the present invention. In addition, the treatment liquid of the present invention can be impregnated into a nonwoven fabric and then contacted with the surface of the object.

[0114] When spraying or applying the treatment liquid of the present invention onto the surface of an object, the treatment liquid of the present invention can be filled in a container equipped with a sprayer, made into droplets or bubbles and then sprayed, or the treatment liquid of the present invention can be poured from the container onto the surface and applied using a brush or the like.

[0115] The treatment liquid of the present invention is preferably made into a bubble and then contacted with the surface of the object. When the treatment liquid of the present invention is made into a bubble and then contacted with the surface of the object, the treatment liquid of the present invention can adhere to the surface of the object for a long time because the persistence of the bubble is greatly improved, and the treatment liquid of the present invention can adhere to the surface of the object over a large area even with the same amount of liquid, and will not drip, so that the inactivation performance of viruses or bacteria can be further improved.

[0116] Examples of the container having a spray device include a manual spray device that does not use a propellant, such as a trigger spray container and a pump spray container, and an atomizer that uses a propellant.

[0117] The container with a sprayer is preferably a trigger sprayer that can spray the contents in droplet or bubble form, and more preferably a trigger sprayer with a mechanism for spraying the contents in droplet form or a mechanism for forming bubbles (bubble forming mechanism).

[0118] When the treatment liquid of the present invention is impregnated into a nonwoven fabric and then brought into contact with the surface of an object, the nonwoven fabric may be processed into a sheet. The fibers constituting the nonwoven fabric are preferably composed of one or more fibers selected from hydrophilic fibers and hydrophobic fibers.

[0119] In the present invention, the so-called hydrophilic fiber refers to a fiber having a moisture content (20°C, 65% RH) greater than 5% by mass in a standard state. It should be noted that the moisture content in a standard state is measured by the method specified in JISL 1013 and JISL 1015. In addition, the so-called hydrophobic fiber refers to a fiber having a moisture content (20°C, 65% RH) of 5% by mass or less in a standard state.

[0120] Regarding the method of contacting the surface of an object, it is sufficient to place a non-woven fabric impregnated with the treatment liquid of the present invention against the surface of the object, apply external force within a range that does not cause damage to the object, and move the treatment liquid of the present invention impregnated in the non-woven fabric to contact the surface of the object. Any of wiping, rubbing, and patting can be performed.

[0121] The amount of the treatment liquid used in the present invention is not particularly limited, for example, 2 The amount of component (A) per unit area can be preferably set to 0.05 μg / cm from the viewpoint of virus or bacteria inactivation performance. 2 More preferably, 1 μg / cm 2 From the perspective of cost, it is preferably 15 mg / cm 2 Below, more preferably set to 1 mg / cm 2 the following.

[0122] Regarding the time (standing time) for which the treatment liquid of the present invention is allowed to contact the surface of the object where the virus or bacteria exist, from the viewpoint of the inactivation performance of the virus or bacteria, it is preferably 10 seconds or more, more preferably 1 minute or more, further preferably 5 minutes or more, and is preferably 60 minutes or less, more preferably 30 minutes or less, further preferably 20 minutes or less.

[0123] After contact, the surface may be dried as it is, wiped with a clean cloth, or washed with water. When washing, an external force (physical force) may be applied with a sponge, or simply washed with a stream of water.

[0124] In addition to the above-mentioned embodiments, the present invention also discloses the following aspects.

[0125] <1> A method for inactivating viruses or bacteria, wherein a treatment liquid containing (A) a quaternary ammonium salt surfactant (hereinafter referred to as component (A)), (B) an aliphatic alcohol (hereinafter referred to as component (B)) and water is brought into contact with a surface of an object, thereby inactivating one or more viruses or bacteria selected from the group consisting of enveloped viruses, bacteria of the genus Moraxella and bacteria of the genus Micrococcus present on the surface of the object.

[0126] <2> The method for inactivating viruses or bacteria according to <1> above, wherein component (A) is one or more selected from the group consisting of a compound represented by the following general formula (a1) (hereinafter referred to as component (a1)) and a compound represented by the following general formula (a2) (hereinafter referred to as component (a2)).

[0127] [Chemistry 5]

[0128]

[0129] 〔In the formula, R 1a is an aliphatic hydrocarbon group having 8 or more and 18 or less carbon atoms, R 2a is a group selected from an aliphatic hydrocarbon group having 8 to 18 carbon atoms, an alkyl group having 1 to 3 carbon atoms, and a hydroxyalkyl group having 1 to 3 carbon atoms, and R 3a and R 4a Each is independently a group selected from an alkyl group having 1 to 3 carbon atoms and a hydroxyalkyl group having 1 to 3 carbon atoms, and X- is an anion.]

[0130] [Chemistry 6]

[0131]

[0132] 〔In the formula, R 5a is an aliphatic hydrocarbon group having 8 or more and 18 or less carbon atoms, R 6a and R 7a Each is independently a group selected from an alkyl group having 1 to 3 carbon atoms and a hydroxyalkyl group having 1 to 3 carbon atoms, and X- is an anion.]

[0133] <3> The method for inactivating viruses or bacteria according to <2> above, wherein in the general formula (a1), R 1a is an alkyl or alkenyl group having 8 or more carbon atoms, preferably 18 or less carbon atoms, more preferably 14 or less carbon atoms, and further preferably 10 or less carbon atoms, preferably an alkyl group, R 2a is a group selected from an aliphatic hydrocarbon group having 8 to 18 carbon atoms, an alkyl group having 1 to 3 carbon atoms, and a hydroxyalkyl group having 1 to 3 carbon atoms, preferably an aliphatic hydrocarbon group having 8 to 18 carbon atoms, more preferably 14 to 10 carbon atoms, and preferably an alkyl group or an alkenyl group, more preferably an alkyl group, R 3a and R 4aW is independently a group selected from an alkyl group having 1 to 3 carbon atoms and a hydroxyalkyl group having 1 to 3 carbon atoms, preferably an alkyl group having 1 to 3 carbon atoms, and X- is an anion, preferably an anion selected from a halogen ion and an alkyl sulfate ion having 1 to 3 carbon atoms, more preferably an anion selected from a chloride ion, a bromide ion, an iodide ion, a methyl sulfate ion, an ethyl sulfate ion and a propyl sulfate ion.

[0134] <4> The method for inactivating viruses or bacteria according to <2> or <3>, wherein in the general formula (a2), R 5a is an alkyl or alkenyl group having 8 or more, more preferably 10 or more, further preferably 12 or more, and 18 or less, more preferably 16 or less, further preferably 14 or less carbon atoms, preferably an alkyl group, R 6a and R 7a Each is independently a group selected from an alkyl group having 1 to 3 carbon atoms and a hydroxyalkyl group having 1 to 3 carbon atoms, preferably an alkyl group having 1 to 3 carbon atoms, and X- is an anion, preferably an anion selected from a halogen ion and an alkyl sulfate ion having 1 to 3 carbon atoms, more preferably an anion selected from a chloride ion, a bromide ion, an iodide ion, a methyl sulfate ion, an ethyl sulfate ion and a propyl sulfate ion.

[0135] <5> The method for inactivating viruses or bacteria according to any one of <1> to <4>, wherein the component (A) contains didecyldimethylammonium salt.

[0136] <6> The method for inactivating viruses or bacteria according to any one of <1> to <5>, wherein the component (B) is an aliphatic alcohol having an aliphatic hydrocarbon group with 8 or more carbon atoms, more preferably 10 or more, even more preferably 12 or more, and 16 or less, more preferably 14 or less, even more preferably 12 or less, and even more preferably 12, preferably an aliphatic alcohol having a linear or branched alkyl group, or a linear or branched alkenyl group, more preferably a linear or branched alkyl group, even more preferably a linear alkyl group.

[0137] <7> The method for inactivating viruses or bacteria according to any one of <1> to <6> above, wherein component (B) is at least one selected from octanol, decanol, dodecyl alcohol, tetradecyl alcohol and hexadecanol, preferably at least one selected from decanol, dodecyl alcohol and tetradecyl alcohol, more preferably at least one selected from dodecyl alcohol and tetradecyl alcohol, and even more preferably dodecyl alcohol.

[0138] <8> A method for inactivating viruses or bacteria according to any one of <1> to <7> above, wherein in the treatment liquid, the mass ratio (B) / (A) of the content of component (A) to the content of component (B) is preferably 1 / 4 or more, more preferably 1 / 3 or more, further preferably 1 / 2 or more, and preferably 10 / 1 or less, more preferably 7 / 1 or less, further preferably 5 / 1 or less, further preferably 3 / 1 or less, further preferably 2 / 1 or less.

[0139] <9> A method for inactivating viruses or bacteria according to any one of <1> to <8>, wherein the content of component (A) in the treatment liquid is preferably 0.1 ppm or more, more preferably 1 ppm or more, further preferably 5 ppm or more, further preferably 20 ppm or more, further preferably 50 ppm or more, and preferably 4000 ppm or less, more preferably 3000 ppm or less, further preferably 1000 ppm or less, further preferably 500 ppm or less, further preferably 300 ppm or less, further preferably 200 ppm or less, further preferably 150 ppm or less, further preferably 100 ppm or less.

[0140] <10> A method for inactivating viruses or bacteria according to any one of <2> to <9>, wherein the treatment liquid contains component (a1) and component (a2) as component (A), and the mass ratio (a2) / (a1) of the content of component (a1) to the content of component (a2) in the treatment liquid is preferably 0 / 10 or more, more preferably 1.5 / 8.5 or more, further preferably 2 / 8 or more, and preferably 8 / 2 or less, more preferably 7 / 3 or less, further preferably 6 / 4 or less, and further preferably 4 / 6 or less.

[0141] <11> A method for inactivating viruses or bacteria according to any one of <1> to <10>, wherein the content of component (B) in the treatment liquid is preferably 0.1 ppm or more, more preferably 1 ppm or more, further preferably 10 ppm or more, further preferably 20 ppm or more, further preferably 50 ppm or more, and preferably 1500 ppm or less, more preferably 1000 ppm or less, further preferably 500 ppm or less, further preferably 250 ppm or less, further preferably 150 ppm or less, further preferably 100 ppm or less, further preferably 50 ppm or less.

[0142] <12> The method for inactivating viruses or bacteria according to any one of <1> to <11>, wherein the treatment liquid further contains (C) a surfactant [excluding component (A)] (hereinafter referred to as component (C)].

[0143] <13> A method for inactivating viruses or bacteria according to any one of <1> to <12>, wherein component (C) is one or more selected from the group consisting of (C1) anionic surfactants [hereinafter referred to as component (C1)], (C2) nonionic surfactants [hereinafter referred to as component (C2)], (C3) semi-polar surfactants [hereinafter referred to as component (C3)] and (C4) amphoteric surfactants [hereinafter referred to as component (C4)].

[0144] <14> The method for inactivating viruses or bacteria according to any one of <1> to <13>, wherein the treatment liquid contains (D) a water-soluble organic solvent [excluding component (B)] (hereinafter referred to as component (D)].

[0145] <15> The method for inactivating viruses or bacteria according to any one of <1> to <14>, wherein the treatment liquid contains (E) an organic acid or a salt thereof (hereinafter referred to as component (E)).

[0146] <16> The method for inactivating a virus or bacteria according to any one of <1> to <15>, wherein the virus or bacteria to be used is influenza virus, human coronavirus, Moraxella osloensis, or Micrococcus luteus, in particular influenza virus, Moraxella osloensis, or Micrococcus luteus.

[0147] <17> The method for inactivating viruses or bacteria according to any one of <1> to <16>, wherein the target surface is a surface of a hard object.

[0148] <18> The method for inactivating viruses or bacteria according to any one of <1> to <16>, wherein the target surface is a surface of livestock or livestock-breeding equipment.

[0149] <19> The method for inactivating viruses or bacteria according to any one of <1> to <18>, wherein the treatment liquid is sprayed or applied onto a surface of an object where the target virus or bacteria exists or is thought to exist.

[0150] <20> The method for inactivating viruses or bacteria according to any one of <1> to <18>, wherein the surface of the object on which the virus or bacteria is present or is thought to be present is immersed in the treatment liquid.

[0151] <21> The method for inactivating viruses or bacteria according to any one of <1> to <18>, wherein the treatment liquid is impregnated into a nonwoven fabric and then brought into contact with a surface of an object where the target virus or bacteria exists or is thought to exist.

[0152] <22> The method for inactivating viruses or bacteria according to any one of <1> to <21>, wherein the amount of the treatment liquid used is 2 The amount of component (A) per unit area is preferably 0.05 μg / cm 2 More preferably, 1 μg / cm 2 More than, and preferably 15 mg / cm 2 Below, more preferably 1 mg / cm 2 the following.

[0153] <23> A method for inactivating viruses or bacteria according to any one of <1> to <22> above, wherein the time (standing time) for which the treatment liquid is in contact with the surface of an object where the virus or bacteria exists is preferably more than 10 seconds, more preferably more than 1 minute, further preferably more than 5 minutes, and preferably less than 60 minutes, more preferably less than 30 minutes, further preferably less than 20 minutes.

[0154] <24> The method for inactivating viruses or bacteria according to any one of <1> to <23>, wherein the treatment liquid is made into a foamy state and then contacted with the surface of the object.

[0155] Example

[0156] <Ingredients>

[0157] In Examples and Comparative Examples, the following components were used.

[0158] <(A)Component>

[0159] BAC: alkylbenzyldimethylammonium chloride, R in the general formula (a2) 5a is an alkyl group having 8 to 18 carbon atoms, R 6a and R 7a A compound in which X- is a methyl group and X- is a chloride ion, component (a2), SANISOL C (active ingredient 50%), manufactured by Kao Corporation

[0160] ·DDAC: didecyldimethylammonium chloride, R in the general formula (a1) 1a and R 2a is an alkyl group having 10 carbon atoms, R 3a and R 4a A compound in which X- is a methyl group and X- is a chloride ion; component (a1); COTAMINE D-10P (active ingredient 75%); manufactured by Kao Corporation

[0161] ·DDAMS: didecyldimethylammonium methyl sulfate, R in the general formula (a1) 1a and R 2a is an alkyl group having 10 carbon atoms, R 3aand R 4a Methyl, X - Compound of methylsulfuric acid, component (a1), synthesized by the following method (active ingredient 84%)

[0162] <(B) Ingredient>

[0163] -C12OH: Dodecyl alcohol, KALCOL 2098, manufactured by Kao Co., Ltd.

[0164] -C14OH: Tetradecyl alcohol, KALCOL 4098, manufactured by Kao Co., Ltd.

[0165] <(C) Ingredients>

[0166] AG-10: Decyl glucoside, (C2) component, MYDOL 10 (active ingredient 40%), manufactured by Kao Corporation

[0167] AG-12: Lauryl glucoside, (C2) component, MYDOL 12 (active ingredient 40%), manufactured by Kao Corporation

[0168] ·Lauryl dimethyl amine oxide: R in the general formula (c3) 1c is an alkyl group having 12 carbon atoms, R 2c and R 3c A compound wherein methyl is present, q and p are 0, component (C3), ANHITOL 20N (active ingredient 35%), manufactured by Kao Corporation

[0169] ·Lauryl dimethylaminoacetic acid betaine: R in the general formula (c4) 4c is an alkyl group with 12 carbon atoms, r is 0, R 6c and R 7c Methyl, R 8c A compound in which 2-(4-hydroxy-1-oxo-)-1-nitropropene is a methylene group and B is -COO-; component (C4); ANHITOL 24B (active ingredient 27%); manufactured by Kao Corporation

[0170] Pentaerythritol propoxide: AGRIZOLE F-100, manufactured by Kao Corporation

[0171] <(D) Ingredient>

[0172] ·Ethanol: Made by Fujifilm Wako Pure Chemical Industries, Ltd., (D4) ingredient

[0173] · Isopropyl alcohol: Made by Fujifilm Wako Pure Chemical Industries, Ltd. (D4)

[0174] <(E) Ingredient>

[0175] -Sodium gluconate: Sodium gluconate, manufactured by Fujifilm Wako Pure Chemical Industries, Ltd.

[0176] ·Sodium citrate: Sodium citrate, manufactured by Fujifilm Wako Pure Chemical Industries, Ltd.

[0177] [Synthesis of DDAMS]

[0178] 58.31 g of didecylmethylamine (manufactured by Tokyo Chemical Industry Co., Ltd.) and 15 g of propylene glycol were added to a four-necked flask and the temperature was raised to 45°C. While the temperature was raised from 45°C to 65°C, 22.85 g of dimethylsulfate (0.98 eq. / amine) was added dropwise over 2.5 hours and the mixture was aged at 65°C. After the reaction was completed, 5 g of ion exchange water was added and the mixture was heated at 65°C for 2 hours to synthesize DDAMS. The effective content was 84%.

[0179] [Examples 1 to 4, Comparative Examples 1 to 2]

[0180] [Virus inactivation test method]

[0181] The method of the virus inactivation test is as follows.

[0182] (1) Preparation of test solution and control solution

[0183] BAC was added to a volumetric flask in an amount such that the prepared active ingredient was 1% by mass, and the volume was fixed to 10 mL with ethanol to prepare a BAC 1% by mass solution.

[0184] DDAC was added to a 10 mL volumetric flask in such an amount that the prepared active ingredient was 1% by mass, and the volume was fixed to 10 mL with ethanol to prepare a DDAC 1% by mass solution.

[0185] 0.5 g of C12OH was added to a 10 mL volumetric flask, and the volume was fixed to 10 mL with ethanol to prepare a C12OH 5 mass % solution.

[0186] 92.24 g of calcium chloride dihydrate (manufactured by FUJIFILM Wako Pure Chemical Industries, Ltd.) and 54.58 g of magnesium chloride hexahydrate (manufactured by FUJIFILM Wako Pure Chemical Industries, Ltd.) were dissolved in 1 L of sterilized ion-exchanged water to prepare 5000° DH water.

[0187] The ion exchange water was sterilized by autoclaving (121° C.×20 min), and the pH was adjusted to 7 with 1N hydrochloric acid (manufactured by Kanto Chemical Co., Ltd.) to prepare sterile ion exchange water.

[0188] In order to form the composition of the test solution in Table 1, a BAC 1 mass % solution, a DDAC 1 mass % solution, a C12OH 5 mass % solution, and sterilized ion exchange water were added to a sample bottle, and 5000° DH water was added to make the hardness 8° DH to prepare the test solution in Table 1. It should be noted that the amount of each component in each test solution in Table 1 is an effective component.

[0189] Separately, 100 μL of 99.5% ethanol, 16 μL of 5000° DH water, and 9884 mL of sterilized ion-exchanged water were added to a sample bottle to prepare a control solution.

[0190] 45 μL of each of the prepared test solutions and control solutions were dispensed into sterile tubes and allowed to stand at room temperature until used in the test.

[0191] (2) Test virus

[0192] InfluenzaA virus(H 1N 1,A / PR / 8 / 34)ATCC(American TypeCultureCollection)VR-1469

[0193] (3) Preparation of test virus solution

[0194] In T175 flasks, the cells were cultured at confluence (2 × 10 7 MDCK cells (dog kidney-derived cells, ATCC CCL-34, ATCC) were cultured in 1% flask (cells / flask), washed with PBS (D-PBS (-) / pH 7.4, Wako), and then infected with Influenza A virus (H1N1, A / PR / 8 / 34) in an amount to give an MOI of 0.001 was added to 40 mL of a serum-free medium (Gibco, Hybridoma Serum-Free Medium, P / N 123-00067, hereinafter referred to as SFM) supplemented with acetylated trypsin (Sigma) at a final concentration of 2 μg / mL and 50 mg / L gentamicin (gentamicin sulfate solution (50 mg / ml), Fujifilm Wako Pure Chemical Industries, Ltd.). The cells were incubated at 5% CO 2 After culturing at 37°C for about 48 hours, the cell culture supernatant was recovered, and the supernatant that had been centrifuged (800g / 10min at 4°C) was centrifuged again (13000g / 10min at 4°C) to remove the supernatant, thereby obtaining a virus concentrate (precipitate). The virus concentrate was resuspended in 150-200μL of SFM, and then further centrifuged (800g / 10min at 4°C) to recover the supernatant, thereby obtaining a concentrated Influenza A virus solution. The virus titer of the concentrated Influenza A virus solution was measured using Focus Assay, and the virus titer was adjusted to 2×10 based on the measurement results. 8 FFU / mL, and the resulting solution was used as the test virus solution.

[0195] The virus titer based on focus analysis was determined using the following method.

[0196] In the focus analysis, 12-well plates were cultured in Eagle's minimum essential medium (MEM medium) supplemented with 5% FBS in a manner that MDCK cells were confluent, washed with PBS, and then acclimated in SFM for 30 minutes. The reacted sample was added to the MDCK cells cultured in the above-mentioned 12-well plates at a volume of 500 μL / well and incubated for 30 minutes to thereby infect the influenza virus. This experiment was performed using a triple assay. After infection, a SFM-based washing operation was performed, and 1.2 w / v%-Ceolus (Asahi Kasei Chemicals, RC591) and 2.0 μg / mL-SFM containing acetylated trypsin (manufactured by Sigma) were added to 2.0 mL / well and cultured for 18-22 hours. After culture, the wells were washed 3 times with PBS, and 100% methanol (manufactured by Wako) was added to fix the cells. The fixed cells were reacted with the primary antibody: Anti-NPantibody (mouse hybridoma (4E6) cell culture supernatant (used in J Virol. 2008; 82: 5940-50)) and the secondary antibody: HRP-linked goat Anti-mouse IgG+IgM antibody (manufactured by Jackson Immuno Research Laboratories), and the HRP was reacted with DEPDA reaction solution (100 mM citrate buffer (pH 6.0) containing 1.2 mM N,N-diethyl-p-phenylenediamine dihydrochloride (manufactured by Fujifilm Wako Pure Chemical Industries, Ltd.), 0.003% hydrogen peroxide, and 2 mM 4-chloro-1-naphthol (manufactured by Fujifilm Wako Pure Chemical Industries, Ltd.)) to count the number of stained foci. The foci analysis was performed by independent triplicate measurements. The values ​​represent the average of the triplicate measurements.

[0197] (4) Preparation of diluent for measurement (SCDLP solution)

[0198] 38 g of SCDLP powder (manufactured by Nippon Pharmaceutical Co., Ltd., P / N 395-00265) was weighed and dissolved in 1 L of ion-exchanged water, followed by autoclave treatment (121° C.×20 min).

[0199] (5) Test operation

[0200] 1. Add 5 μL of each test virus solution to 45 μL of the test solution or control solution in Table 1, immediately stir with a vortex mixer for 15 seconds, and then let stand.

[0201] 2. 5 minutes after contact (addition of the test virus solution), add 950 μL of SCDLP, stir for 10 seconds using a vortex mixer, and then perform 10-fold serial dilutions using SFM.

[0202] 3. 500 μL of the solution diluted with SFM was inoculated into 3 wells of a 12-well plate on MDCK cells at a confluent state.

[0203] 4. After 18 to 22 hours, the infection titer (FFU / mL) of the inoculated solution was determined using the focus analysis method described above.

[0204] (6) Calculation of virus reduction

[0205] The virus reduction was calculated from the difference in the logarithm of the infection titer between the control solution and the test solution, ΔLOG (FFU / mL). The results are shown in Table 1. It can be said that the larger the ΔLOG (FFU / mL) of the test solution, the higher the virus or bacteria inactivation effect.

[0206] [Table 1]

[0207]

[0208] In Table 1, the viral reduction ΔLOG (FFU / mL) expressed as “>4.38” means that the virus was reduced to below the viral detection limit.

[0209] [Examples 5 to 20]

[0210] [Bacteria inactivation test method]

[0211] The method of the bacteria inactivation test is as follows.

[0212] (1) Preparation of test solution and control solution

[0213] ·Examples 5 to 10

[0214] 10 g of DDAMS as an active ingredient, 5 g of C12OH, 20 g of AG-10 or AG-12 as an active ingredient, and 15 g of ethanol were added to a sample bottle and stirred. Sterile ion exchange water was added to make the total amount 100 g, and stirred to obtain a formula liquid. 0.1 g of the formula liquid was diluted with 39.9 g of sterile ion exchange water to obtain the test liquid of Table 2 (Examples 5 and 6).

[0215] Examples 7 and 8 were obtained by diluting 0.1 g of the formula liquid with 99.9 g of sterilized ion-exchanged water, and Examples 9 and 10 were obtained by diluting 0.1 g of the formula liquid with 199.9 g of sterilized ion-exchanged water.

[0216] -Examples 11 to 13, 19

[0217] A formula solution was prepared by mixing 2.50 g of DDAMS as an active ingredient, 1.25 g of C12OH, 1.25 g of lauryl dimethylamine oxide as an active ingredient, 3.75 g of lauryl dimethylaminoacetic acid betaine as an active ingredient, 0.38 g of sodium gluconate, 0.05 g of sodium citrate, and 3.75 g of ethanol. 0.027 g of the formula solution was diluted with 4.973 g of sterilized ion exchange water to obtain a test solution of Example 11.

[0218] The test solution of Example 12 was obtained by diluting 0.054 g of the formulated solution prepared in Example 11 with 4.946 g of sterilized ionized water.

[0219] The test solution of Example 13 was obtained by diluting 0.108 g of the formulated solution prepared in Example 11 with 4.892 g of sterilized ionized water.

[0220] The test solution of Example 19 was obtained by diluting 0.027 g of the formulated solution prepared in Example 11 with 49.973 g of sterilized ionized water.

[0221] -Example 14

[0222] A formula solution was prepared by mixing 2.50 g of DDAMS as an active ingredient, 1.25 g of C12OH, 2.45 g of lauryl dimethylamine oxide as an active ingredient, 7.49 g of lauryl dimethylaminoacetic acid betaine as an active ingredient, 0.38 g of sodium gluconate, 0.05 g of sodium citrate, and 3.75 g of ethanol. 0.045 g of the formula solution was diluted with 5 g of sterilized ion exchange water to obtain the test solution of Example 14.

[0223] ·Examples 15 to 17, 20

[0224] A formula solution was prepared by mixing 10 g of DDAMS, 2.5 g of C12OH, 10 g of propoxypentaerythritol, 0.75 g of sodium gluconate, 0.10 g of sodium citrate, 3.5 g of isopropyl alcohol, and 19.01 g of sterile ion exchange water as active ingredients. 0.025 g of the formula solution was diluted with 4.975 g of sterile ion exchange water to obtain the test solution of Example 15.

[0225] The test solution of Example 16 was obtained by diluting 0.050 g of the formulated solution prepared in Example 15 with 4.950 g of sterilized ionized water.

[0226] The test solution of Example 17 was obtained by diluting 0.100 g of the formulated solution prepared in Example 15 with 4.900 g of sterilized ionized water.

[0227] The test solution of Example 20 was obtained by diluting 0.025 g of the formulated solution prepared in Example 15 with 99.975 g of sterilized ionized water.

[0228] Example 18

[0229] A formula solution was prepared by mixing 5 g of DDAMS as an active ingredient, 1.25 g of C12OH, 20 g of propoxypentaerythritol, 0.375 g of sodium gluconate, 0.05 g of sodium citrate, 1.75 g of isopropyl alcohol, and 19.5 g of sterile ion exchange water. 0.05 g of the formula solution was diluted with 4.95 g of sterile ion exchange water to obtain the test solution of Example 18.

[0230] 5 mL of each prepared test solution was dispensed into a sterile test tube, and 5 mL of sterile ion exchange water was dispensed into a sterile test tube as a control solution, and all were left to stand at room temperature until used in the test.

[0231] It should be noted that the blending amount of each component in each test solution in Table 2 and Table 3 is an effective component.

[0232] (2) Test bacteria

[0233] Moraxella osloensis (clone isolates)

[0234] (3) Preparation of test bacterial solution

[0235] From the glycerol stock of each bacterium stored at -80°C in 10% glycerol (manufactured by Fujifilm Wako Pure Chemical Industries, Ltd.), the culture was scraped once into SCD liquid medium (SCD medium "DAIGO", manufactured by Nippon Pharmaceutical Co., Ltd.) and cultured overnight at 37°C. The cultured bacterial liquid was centrifuged (5 minutes, 4500g, 4°C), and after removing the supernatant, 10 ml of physiological saline was added to suspend it. After repeating the centrifugation and supernatant removal operations twice in the same manner, the OD600 was adjusted to 1 in physiological saline using a turbidity meter (Biowave Cell Density Meter CO8000, manufactured by Biochrom) so that the bacterial count was 10 9 cfu / mL.

[0236] (4) Test operation

[0237] 1. 50 μL of the test bacterial solution prepared in (3) was added to 5 mL of the test solution or control solution, and the mixture was immediately stirred for 15 seconds using a vortex mixer and then stirred in a BIO SHAKER (SIC-320HX, manufactured by AS ONE) (150 rpm / 25°C).

[0238] 2. 5 minutes after contact (addition of the test bacterial solution), add 500 μL to a sterilized test tube pre-filled with 4.5 mL of Lecithin-Polysorbate (LP) diluent (LP diluent "DAIGO", manufactured by Nippon Pharmaceutical Co., Ltd.). Stir for 10 seconds using a vortex mixer. Then perform a 10-fold serial dilution with the LP diluent.

[0239] 3. 100 μL of the diluted solution of each gradient was applied to SCD agar medium (manufactured by Nippon Pharmaceutical Co., Ltd.) and cultured at 37°C overnight.

[0240] 4. After incubation, count the number of colonies formed on the agar medium and calculate the number of surviving bacteria.

[0241] (5) Calculation of Bacteria Reduction Amount

[0242] The bacterial reduction was calculated from the difference in logarithm of the number of viable bacteria between the control solution and the test solution, ΔLOG (cfu / mL). The results are shown in Tables 2 and 3. It can be said that the larger the ΔLOG (cfu / mL) of the test solution, the higher the bacterial inactivation effect.

[0243] [Table 2]

[0244]

[0245] [Table 3]

[0246]

[0247] In Tables 2 and 3, the expression of ">5.0" for the bacterial reduction amount ΔLOG (cfu / mL) means that the bacteria were reduced to below the bacterial detection limit.

[0248] [Examples 21 to 27, Comparative Examples 3 to 6]

[0249] [Bacteria inactivation test method]

[0250] The method of the bacteria inactivation test is as follows.

[0251] (1) Preparation of test solution and control solution

[0252] Test solutions and control solutions were prepared by the same method as described in "(1) Preparation of test solutions and control solutions" of Examples 5 to 20 to form the formulations described in Table 4. It should be noted that the formulation amounts of the components in the test solutions in Table 4 are all effective components.

[0253] (2) Test bacteria

[0254] Moraxella osloensis (clone isolates)

[0255] (3) Preparation of test bacterial solution

[0256] A test bacterial solution was prepared in the same manner as described in (3) of the bacterial inactivation test method of Examples 5 to 20.

[0257] (4) Test operation

[0258] The test operation was carried out in the same manner as the method described in (4) of the bacteria inactivation test method of Examples 5 to 20.

[0259] (5) Calculation of Bacteria Reduction Amount

[0260] The bacterial reduction was calculated from the difference ΔLOG (cfu / mL) between the logarithms of the number of viable bacteria in the control solution and the test solution. The results are shown in Table 4. It can be said that the larger the ΔLOG (cfu / mL) of the test solution, the higher the bacterial inactivation effect.

[0261] [Appearance evaluation of test solution]

[0262] 10 mL of each test solution was added to a glass sample bottle, and the appearance of each test solution was visually confirmed and evaluated according to the following criteria. The results are shown in Table 4. When insoluble matter is confirmed in the test solution, clogging may occur when the test solution is sprayed using a sprayer, or the bactericidal performance may be reduced due to the insoluble matter, so the appearance of the test solution is preferably transparent.

[0263] 4: Transparent, no insoluble matter was confirmed.

[0264] 3: Although transparent, insoluble matter was slightly observed.

[0265] 2: Although transparent, insoluble matter was clearly observed.

[0266] 1: Completely turbid.

[0267] [Table 4]

[0268]

[0269] [Examples 28 to 30]

[0270] [Bacteria inactivation test method]

[0271] The method of the bacteria inactivation test is as follows.

[0272] (1) Preparation of test solution and control solution

[0273] Test solutions and control solutions were prepared by the same method as described in "(1) Preparation of test solutions and control solutions" of Examples 5 to 20 to form the formulations described in Table 5. It should be noted that the formulation amounts of the components in the test solutions in Table 5 are all effective components.

[0274] (2) Test bacteria

[0275] Moraxella osloensis (clone isolate)

[0276] (3) Preparation of test bacterial solution

[0277] A test bacterial solution was prepared in the same manner as described in (3) of the bacterial inactivation test method of Examples 5 to 20.

[0278] (4) Test operation

[0279] The test operation was carried out in the same manner as the method described in (4) of the bacteria inactivation test method of Examples 5 to 20.

[0280] (5) Calculation of Bacteria Reduction Amount

[0281] The bacterial reduction was calculated from the difference ΔLOG (cfu / mL) between the logarithms of the number of surviving bacteria in the control solution and the test solution. The results are shown in Table 5. It can be said that the larger the ΔLOG (cfu / mL) of the test solution, the higher the bacterial inactivation effect.

[0282] [Table 5]

[0283]

[0284] [Example 31, Comparative Examples 8-9]

[0285] [Bacteria inactivation test method]

[0286] The method of the bacteria inactivation test is as follows.

[0287] (1) Preparation of test solution and control solution

[0288] Test solutions and control solutions were prepared by the same method as described in "(1) Preparation of test solutions and control solutions" of Examples 5 to 20 to form the formulations described in Table 6. It should be noted that the formulation amounts of the components in the test solutions in Table 6 are all effective components.

[0289] (2) Test bacteria

[0290] Micrococcus luteus (Chlamydia isolate)

[0291] (3) Preparation of test bacterial solution

[0292] A test bacterial solution was prepared in the same manner as described in (3) of the bacterial inactivation test method of Examples 5 to 20, except that the test bacteria was changed to Micrococcus luteus.

[0293] (4) Test operation

[0294] The test operation was carried out in the same manner as the method described in (4) of the bacterial inactivation test method of Examples 5 to 20, except that the test bacteria were changed to Micrococcus luteus.

[0295] (5) Calculation of Bacteria Reduction Amount

[0296] The bacterial reduction was calculated from the difference ΔLOG (cfu / mL) between the logarithms of the number of viable bacteria in the control solution and the test solution. The results are shown in Table 6. It can be said that the larger the ΔLOG (cfu / mL) of the test solution, the higher the bacterial inactivation effect.

[0297] [Table 6]

[0298]

[0299] [Example 32, Comparative Examples 10-11]

[0300] [Bacteria inactivation test method on substrate]

[0301] The method of the bacterial inactivation test on the substrate is as follows.

[0302] (1) Preparation of test solution and control solution

[0303] Test solutions and control solutions were prepared by the same method as described in "(1) Preparation of test solutions and control solutions" of Examples 5 to 20 to form the formulations described in Table 7. It should be noted that the formulation amounts of the components in the test solutions in Table 7 are all effective components.

[0304] (2) Test bacteria

[0305] Moraxella osloensis (clone isolate)

[0306] (3) Preparation of test bacterial solution

[0307] A test bacterial solution was prepared in the same manner as described in (3) of the bacterial inactivation test method of Examples 5 to 20.

[0308] (4) Test operation

[0309] 1. Add 10 μL of the test bacterial solution prepared in (3) to a test substrate (SUS304 (2B), φ20×2.0, manufactured by STANDARD TEST PIECE Co., Ltd.) placed in a dish, spread over the entire test substrate with a cell spreader, and dry at 36°C for 30 minutes.

[0310] 2. Place 300 μL of each test solution or control solution on the dried test substrate and let it stand for 5 minutes.

[0311] 3. 10 mL of Lecithin-Polysorbate (LP) diluent (LP diluent "DAIGO", manufactured by Nippon Pharmaceutical Co., Ltd.) was placed in a dish to extract bacteria from the test substrate. The extracted LP diluent was serially diluted 10-fold.

[0312] 4. 100 μL of the diluted solution of each gradient was applied to SCD agar medium (manufactured by Nippon Pharmaceutical Co., Ltd.) and cultured at 37°C overnight.

[0313] 5. After the culture, the number of colonies formed on the agar medium was counted, and the number of surviving bacteria per substrate was calculated.

[0314] (5) Calculation of Bacteria Reduction Amount

[0315] The bacterial reduction was calculated from the difference in the logarithm of the number of surviving bacteria between the control solution and the test solution, ΔLOG (cfu / carrier). The results are shown in Table 7. It can be said that the larger the ΔLOG (cfu / carrier) of the test solution, the higher the bacterial inactivation effect.

[0316] [Table 7]

[0317]

[0318] [Examples 33 to 35, Comparative Examples 12 to 14]

[0319] [Bubble persistence test]

[0320] The method of the bubble persistence test is as follows.

[0321] (1) Preparation of test solution

[0322] BAC was added to a 10 mL volumetric flask in an amount such that the prepared active ingredient was 1% by mass, and the volume was fixed to 10 mL with ethanol to prepare a BAC 1% by mass solution.

[0323] DDAC was added to a 10 mL volumetric flask in such an amount that the prepared active ingredient was 1% by mass, and the volume was fixed to 10 mL with ethanol to prepare a DDAC 1% by mass solution.

[0324] 0.5 g of C12OH was added to a 10 mL volumetric flask, and the volume was fixed to 10 mL with ethanol to prepare a C12OH 5 mass % solution.

[0325] 0.5 g of C14OH was added to a 10 mL volumetric flask, and the volume was fixed to 10 mL with ethanol to prepare a C14OH 5 mass % solution.

[0326] 92.24 g of calcium chloride dihydrate (manufactured by FUJIFILM Wako Pure Chemical Industries, Ltd.) and 54.58 g of magnesium chloride hexahydrate (manufactured by FUJIFILM Wako Pure Chemical Industries, Ltd.) were dissolved in 1 L of sterilized ion-exchanged water to prepare 5000° DH water.

[0327] The ion exchange water was sterilized by autoclaving (121° C.×20 min), and the pH was adjusted to 7 with 1N hydrochloric acid (manufactured by Kanto Chemical Co., Ltd.) to prepare sterile ion exchange water.

[0328] In order to form the composition of the test solution in Table 8, a BAC 1 mass % solution, a DDAC 1 mass % solution, a C12OH 5 mass % solution, a C14OH 5 mass % solution, and sterilized ion exchange water were added to the sample bottle, and 5000° DH water was added to make the hardness 8° DH, thereby preparing the test solution in Table 8. It should be noted that the amount of each component in each test solution in Table 8 is an effective component.

[0329] (2) Foam persistence test method

[0330] 1. Add 5 mL of each test solution to a 10 mL sterile test tube (manufactured by Eiken Chemical Co., Ltd.) and cap it.

[0331] 2. Use your hands to shake up and down vigorously 20 times.

[0332] 3. The height of the bubbles after standing for 15 minutes was confirmed using a scale, and the bubble performance was determined according to the following criteria. The results are shown in Table 8.

[0333] <Evaluation of Foam Performance>

[0334] 4: Bubble height is 0.5mL or more

[0335] 3: Bubble height is 0.3~0.5mL

[0336] 2: Bubble height is less than 0.3mL

[0337] 1: Bubble height is 0mL

[0338] [Table 8]

[0339]

[0340] Even if conventional disinfectant liquid is sprayed onto an object using a sprayer and adheres to the object surface in the form of bubbles, the bubbles will burst and drip, so that the liquid cannot remain on the surface of the object, and the inactivation performance of viruses or bacteria is reduced.

[0341] As the treatment liquid of the present invention, the persistence of bubbles is greatly improved compared with Comparative Examples 12 to 14. Even with the same amount of liquid, the bubbles are attached to a large area without dripping, and thus can be attached to the surface of the object for a long time. It can be inferred that this is because the aliphatic hydrocarbon group as the hydrophobic group of component (A) and component (B) are deposited due to hydrophobic interaction to form a firm bubble film. Therefore, the treatment liquid of the present invention can also improve the inactivation performance of viruses or bacteria when it is sprayed onto the object with a sprayer and attached to the surface of the object in the form of bubbles.

Claims

1. A method for inactivating viruses or bacteria, wherein: A treatment liquid containing A quaternary ammonium salt surfactant, B aliphatic alcohol and water is brought into contact with the surface of the object to inactivate one or more viruses or bacteria selected from enveloped viruses, Moraxella bacteria and Micrococcus bacteria present on the surface of the object, Hereinafter, A quaternary ammonium salt type surfactant is referred to as A component, and B aliphatic alcohol is referred to as B component.

2. The method for inactivating viruses or bacteria according to claim 1, wherein: Component A is one or more selected from the group consisting of compounds represented by the following general formula a1 and compounds represented by the following general formula a2; In formula a1, R 1a is an aliphatic hydrocarbon group having 8 or more and 18 or less carbon atoms, R 2a is a group selected from an aliphatic hydrocarbon group having 8 to 18 carbon atoms, an alkyl group having 1 to 3 carbon atoms, and a hydroxyalkyl group having 1 to 3 carbon atoms, and R 3a and R 4a are each independently a group selected from an alkyl group having 1 to 3 carbon atoms and a hydroxyalkyl group having 1 to 3 carbon atoms, and X - It is an anion; In formula a2, R 5a is an aliphatic hydrocarbon group having 8 or more and 18 or less carbon atoms, R 6a and R 7a are each independently a group selected from an alkyl group having 1 to 3 carbon atoms and a hydroxyalkyl group having 1 to 3 carbon atoms, and X - It is an anion.

3. The method for inactivating viruses or bacteria according to claim 1 or 2, wherein: Component A contains didecyldimethylammonium salt.

4. The method for inactivating viruses or bacteria according to any one of claims 1 to 3, wherein: The component B is an aliphatic alcohol having 8 to 16 carbon atoms.

5. The method for inactivating a virus or bacteria according to any one of claims 1 to 4, wherein: The component B is one or more selected from the group consisting of dodecyl alcohol and tetradecyl alcohol.

6. The method for inactivating viruses or bacteria according to any one of claims 1 to 5, wherein: The mass ratio B / A of the content of the component A to the content of the component B in the treatment liquid is 1 / 4 or more and 10 / 1 or less.

7. The method for inactivating viruses or bacteria according to any one of claims 1 to 6, wherein: The content of the component A in the treatment liquid is 5 ppm or more and 3000 ppm or less.

8. The method for inactivating viruses or bacteria according to any one of claims 1 to 7, wherein: The enveloped virus is an influenza virus.

9. The method for inactivating viruses or bacteria according to any one of claims 1 to 8, wherein: The object surface is the surface of a hard object.

10. The method for inactivating viruses or bacteria according to any one of claims 1 to 8, wherein: The target surface is the surface of livestock or livestock feeding equipment.

Citation Information

Cited By

  • Protonizable amine salt type astaxanthin derivative

    CN122541352A